News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
Subscribe To Our Newsletter & Stay Updated
